Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Jean E Abraham, Karen Pinilla, Alimu Dayimu, Louise Grybowicz, Nikolaos Demiris, Caron Harvey, Lynsey M Drewett, Rebecca Lucey, Alexander Fulton, Anne N Roberts, Joanna R Worley, Anita Chhabra, Wendi Qian, Anne-Laure Vallier, Richard M Hardy, Steve Chan, Tamas Hickish, Devashish Tripathi, Ramachandran Venkitaraman, Mojca Persic, Shahzeena Aslam, Daniel Glassman, Sanjay Raj, Annabel Borley, Jeremy P Braybrooke, Stephanie Sutherland, Emma Staples, Lucy C Scott, Mark Davies, Cheryl A Palmer, Margaret Moody, Mark J Churn, Jacqueline C Newby, Mukesh B Mukesh, Amitabha Chakrabarti, Rebecca R Roylance, Philip C Schouten, Nicola C Levitt, Karen McAdam, Anne C Armstrong, Ellen R Copson, Emma McMurtry, Marc Tischkowitz, Elena Provenzano, Helena M Earl
PARTNER is a prospective, phase II-III, randomised controlled clinical trial, which recruited patients with Triple Negative Breast Cancer (TNBC)1,2 , who were gBRCA wild type (gBRCAwt)3 . Patients (n=559) were randomised on a 1:1 basis to neoadjuvant carboplatin with paclitaxel +/- olaparib 150mg twice daily, days 3 to 14, for 4 cycles (gap schedule olaparib, research arm) followed by 3 cycles of anthracycline chemotherapy before surgery. The primary endpoint was pathological complete response (pCR)4 , and secondary endpoints included event-free survival (EFS), and overall survival (OS)5 ...
April 8, 2024: Nature
#22
JOURNAL ARTICLE
Anna van der Voort, Fleur M Louis, Mette S van Ramshorst, Rob Kessels, Ingrid A Mandjes, Inge Kemper, Mariette J Agterof, Wim A van der Steeg, Joan B Heijns, Marlies L van Bekkum, Ester J Siemerink, Philomeen M Kuijer, Astrid Scholten, Jelle Wesseling, Marie-Jeanne T F D Vrancken Peeters, Ritse M Mann, Gabe S Sonke
BACKGROUND: Patients with stage II-III HER2-positive breast cancer have good outcomes with the combination of neoadjuvant chemotherapy and HER2-targeted agents. Although increasing the number of chemotherapy cycles improves pathological complete response rates, early complete responses are common. We investigated whether the duration of chemotherapy could be tailored on the basis of radiological response. METHODS: TRAIN-3 is a single-arm, phase 2 study in 43 hospitals in the Netherlands...
April 5, 2024: Lancet Oncology
#23
JOURNAL ARTICLE
Antonio Llombart-Cussac, Aleix Prat, José Manuel Pérez-García, José Mateos, Tomás Pascual, Santiago Escrivà-de-Romani, Agostina Stradella, Manuel Ruiz-Borrego, Begoña Bermejo de Las Heras, Marleen Keyaerts, Patricia Galvan, Fara Brasó-Maristany, Juan José García-Mosquera, Thomas Guiot, María Gion, Miguel Sampayo-Cordero, Serena Di Cosimo, Jhudit Pérez-Escuredo, Manuel Atienza de Frutos, Javier Cortés, Geraldine Gebhart
BACKGROUND: The PHERGain study (NCT03161353) is assessing early metabolic responses to neoadjuvant treatment with trastuzumab-pertuzumab and chemotherapy de-escalation using a [18 Fluorine]fluorodeoxyglucose-positron emission tomography ([18 F]FDG-PET) and a pathological complete response-adapted strategy in HER2-positive (HER2+) early breast cancer (EBC). Herein, we present RESPONSE, a PHERGain substudy, where clinicopathological and molecular predictors of [18 F]FDG-PET disease detection were evaluated...
April 8, 2024: European Journal of Nuclear Medicine and Molecular Imaging
#24
Sindhaghatta Venkatram, Maria Duran, Ked Fortuzi, Aam Baqui, Thanh-Ha Luong, Gilda Diaz-Fuentes
Breast cancer affects around 13% of women. Breast cancer gene 1 ( BRCA1 ) carriers are prone to lung and lymph node metastasis, while breast cancer gene 2 ( BRCA2 ) carriers tend to have bone metastasis. Findings of pulmonary nodules, mediastinal lymphadenopathy, and elevated markers such as cancer antigen (CA) 15-3 and CA 27-29 suggest metastatic disease. Here, we present the case of a patient with BRCA1 -positive breast cancer in remission and a history of ovarian cancer with mediastinal lymphadenopathy and pulmonary nodules, with avid fluorodeoxyglucose uptake on positron emission tomography (PET) scan and elevated CA 15-3 and CA 27-29...
March 2024: Curēus
#25
Takumi Sato, Masanori Oshi, Jing Li Huang, Kohei Chida, Arya Mariam Roy, Itaru Endo, Kazuaki Takabe
Purpose: CD133, a cancer stem cells (CSC) marker, has been reported to be associated with treatment resistance and worse survival in triple-negative breast cancer (BC). However, the clinical relevance of CD133 expression in ER-positive/HER2-negative (ER+/HER2-) BC, the most abundant subtype, remains unknown. Methods: The BC cohorts from the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC, n = 1904) and The Cancer Genome Atlas (TCGA, n = 1065) were used to obtain biological variables and gene expression data...
March 27, 2024: Research Square
#26
JOURNAL ARTICLE
Dong-Mei Peng, Juan Li, Jia-Xin Qiu, Lin Zhao
INTRODUCTION: Real-world studies on neoadjuvant dual anti-HER2 therapy combined with chemotherapy for breast cancer (BC) are scarce in China. This study aimed to evaluate the efficacy and safety of neoadjuvant dual anti-HER2 therapy combined with chemotherapy in a real-world setting. Moreover, differences in estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and proliferation cell nuclear antigen (Ki-67) expression pre- and post-neoadjuvant therapy were analyzed...
April 6, 2024: World Journal of Surgical Oncology
#27
JOURNAL ARTICLE
José Manuel Pérez-García, Javier Cortés, Manuel Ruiz-Borrego, Marco Colleoni, Agostina Stradella, Begoña Bermejo, Florence Dalenc, Santiago Escrivá-de-Romaní, Lourdes Calvo Martínez, Nuria Ribelles, Frederik Marmé, Alfonso Cortés, Cinta Albacar, Geraldine Gebhart, Aleix Prat, Khaldoun Kerrou, Peter Schmid, Sofia Braga, Serena Di Cosimo, Maria Gion, Gabriele Antonarelli, Crina Popa, Emilia Szostak, Daniel Alcalá-López, Petra Gener, Jose Rodríguez-Morató, Leonardo Mina, Miguel Sampayo-Cordero, Antonio Llombart-Cussac
BACKGROUND: PHERGain was designed to assess the feasibility, safety, and efficacy of a chemotherapy-free treatment based on a dual human epidermal growth factor receptor 2 (HER2) blockade with trastuzumab and pertuzumab in patients with HER2-positive early breast cancer (EBC). It used an 18 fluorine-fluorodeoxyglucose-PET-based, pathological complete response (pCR)-adapted strategy. METHODS: PHERGain was a randomised, open-label, phase 2 trial that took place in 45 hospitals in seven European countries...
April 3, 2024: Lancet
#28
JOURNAL ARTICLE
Oğuzhan Okcu, Çiğdem Öztürk, Nazlıcan Yalçın, Anıl Can Yalçın, Bayram Şen, Esra Aydın, Ahmet Emin Öztürk
INTRODUCTION: Despite screening, the incidence of breast cancer is increasing worldwide. Neoadjuvant chemotherapy (NAC) response is one of the most important parameters taken into consideration in surgery, optimal adjuvant chemotherapy planning and prognosis prediction. Research on predictive markers for the response to NAC is still ongoing. In our study, we investigated the relationship between tumor-infiltrating neutrophils/mast cells/lymphocytes and NAC response in breast carcinomas...
April 2, 2024: Annals of Diagnostic Pathology
#29
JOURNAL ARTICLE
Jia-Xin Huang, Yi-Jie Chen, Xue-Yan Wang, Jia-Hui Huang, Ke-Hong Gan, Li-Na Tang, Xiao-Qing Pei
BACKGROUND: To develop a convenient modality to predict axillary response to neoadjuvant chemotherapy (NAC) in breast cancer patients. MATERIALS AND METHODS: In this multi-center study, a total of 1019 breast cancer patients with biopsy-proven positive lymph node (LN) receiving NAC were randomly assigned to the training and validation groups at a ratio of 7:3. Clinicopathologic and ultrasound (US) characteristics of both primary tumors and LNs were used to develop corresponding prediction models, and a nomogram integrating clinicopathologic and US predictors was generated to predict the axillary response to NAC...
March 13, 2024: Clinical Breast Cancer
#30
REVIEW
Xiaomeng Jia, Kainan Wang, Qiping Zhuo, Zuowei Zhao, Man Li
Poly-ADP ribose polymerase inhibitor (PARPi) is approved for HER2-negative advanced breast cancer with BRCA1/2 mutation. In recent years, many studies have explored the application of PARPi in neoadjuvant therapy, but failed to reach a unified conclusion. PubMed, Clinicaltrials.gov, Cochrane CENTRAL, Embase, and key oncological meetings for trials were searched for studies reporting neoadjuvant regimens with PARPi in HER2-negative breast cancer. Pathological complete response (pCR), residual cancer burden (RCB), breast-conservation surgery rate (BCSR), clinical response, and adverse events were extracted and pooled in a meta-analysis using the Mantel Haenszel random/fixed effects model...
March 2, 2024: Clinical Breast Cancer
#31
JOURNAL ARTICLE
Yarden Nahmias, Gabriel Yazbek Grobman, Netta Vidavsky
Pathological calcifications, especially calcium phosphate microcalcifications (MCs), appear in most early breast cancer lesions, and their formation correlates with more aggressive tumors and a poorer prognosis. Hydroxyapatite (HA) is a key MC component that crystallizes in the tumor microenvironment. It is often associated with malignant breast cancer lesions and can trigger tumorigenesis in vitro . Here, we investigate the impact of additives on HA crystallization and inhibition, and how precancerous breast cells respond to minerals that are deposited in the presence of these additives...
April 5, 2024: ACS Applied Materials & Interfaces
#32
JOURNAL ARTICLE
Akinari Kakumoto, Tsengelmaa Jamiyan, Hajime Kuroda, Oi Harada, Tomomi Yamaguchi-Isochi, Shogo Baba, Yasutaka Kato, Hiroshi Nishihara, Hiroyuki Kawami
OBJECTIVES: Neutrophils are the most common type of leukocyte in mammals and play an essential role in the innate immune system and anti-cancer responses. However, recent studies identified the presence of tumor-associated neutrophils (TANs) as a poor prognostic factor. The present study investigated whether relationships exist between TANs and the clinicopathological factors and genetic status of breast cancer. METHODS: A total of 196 breast cancer patients with sufficient biopsy, breast-conserving surgery, or mastectomy specimens between 2014 and 2021 in Hokuto Hospital were included...
2024: International Journal of Clinical and Experimental Pathology
#33
JOURNAL ARTICLE
Nurul Wafiqah Saipol Bahrin, Siti Nur Idayu Matusin, Aklimah Mustapa, Lu Zen Huat, Sriyani Perera, Mas Rina Wati Haji Abdul Hamid
BACKGROUND: Breast cancer incidence has been on the rise significantly in the Asian population, occurring at an earlier age and a later stage. The potential predictive value of molecular subtypes, biomarkers, and genetic variations has not been deeply explored in the Asian population. This study evaluated the effect of molecular subtype classification and the presence or absence of biomarkers and genetic variations on pathological complete response (pCR) after neoadjuvant treatment in Asian breast cancer patients...
April 4, 2024: Systematic Reviews
#34
JOURNAL ARTICLE
Geraldine Gebhart, Marleen Keyaerts, Thomas Guiot, Patrick Flamen, Manuel Ruiz-Borrego, Agostina Stradella, Begoña Bermejo, Santiago Escriva-de-Romani, Lourdes Calvo Martínez, Nuria Ribelles, María Fernandez-Abad, Cinta Albacar, Marco Colleoni, Laia Garrigos, Manuel Atienza de Frutos, Florence Dalenc, Aleix Prat, Frederik Marmé, Peter Schmid, Khaldoun Kerrou, Sofia Braga, Petra Gener, Miguel Sampayo-Cordero, Javier Cortés, José Manuel Pérez-García, Antonio Llombart-Cussac
The PHERGain trial investigated the potential of metabolic imaging to identify candidates for chemotherapy deescalation in human epidermal growth factor receptor 2 (HER2)-positive, invasive, operable breast cancer with at least 1 breast lesion evaluable by [18 F]FDG PET/CT. [18 F]FDG PET/CT responders were defined as patients with an SUVmax reduction (ΔSUVmax ) of at least 40% in all of their target lesions after 2 cycles of trastuzumab and pertuzumab (HP) (with or without endocrine therapy). In total, 227 of 285 patients (80%) included in the HP arm showed a predefined metabolic response and received a total of 8 cycles of HP (with or without endocrine therapy)...
April 4, 2024: Journal of Nuclear Medicine
#35
JOURNAL ARTICLE
Ye Zhao, Kai W Wucherpfennig
PURPOSE OF REVIEW: Neoadjuvant (presurgical) immune checkpoint blockade (ICB) has shown promising clinical activity in head and neck cancer and other cancers, including FDA approvals for neoadjuvant approaches for triple-negative breast cancer and nonsmall cell lung cancer. Here we will review recent data from clinical trials in head and neck squamous cell carcinoma (HNSCC), including mechanistic studies highlighting local and systemic effects on T cell-mediated immunity. RECENT FINDINGS: A series of clinical trials of neoadjuvant ICB have documented evidence of clinical activity, including clinical to pathologic downstaging and pathologic response in a subset of patients...
May 1, 2024: Current Opinion in Oncology
#36
Seraphina Choi, Daniel Cassidy, Patricia Castillo, Eric A Mellon, Carmen Calfa
The treatment of breast cancer is largely determined by protein expression assays of estrogen receptor, progesterone receptor, and Her2/neu (HER2) status. These prognostic markers may vary due to tumor heterogeneityor the evolution of prognostic markers throughout the course of treatment. This report presents a case of a patient who initially presented with HER2-negative breast cancer and had rapidly progressed on numerous lines of treatment. An analysis of cerebrospinal fluid via next-generation sequencing and biopsy of metastasis to the liver identified HER2-positive cancer, which allowed for the use of trastuzumab deruxtecan, a HER2-targeted therapy...
March 2024: Curēus
#37
Munaser Alamoodi
The advent of taxane-based chemotherapy has revolutionized breast cancer care. This advance has helped improve the response to downstaging tumors that might otherwise be inoperable. It has also helped in rendering clinically (cN+) positive lymph nodes (LNs) pathologically negative (ypN0). The standard of care for cN+ patients included post-mastectomy radiotherapy (PMRT), regardless of the response to neoadjuvant chemotherapy. However, PMRT in patients with 1-3 positive LNs still lacks definitive guidelines...
April 2024: European Journal of Breast Health
#38
JOURNAL ARTICLE
Juan Alors-Ruiz, Salomé Sanz-Viedma, Francisco Javier Fernández-Garcia, Francisco Sendra-Portero
OBJECTIVE: High rates of negative sentinel lymph node biopsy (SLNB) in clinically node-negative (cN0) breast cancer (BC) after neoadjuvant chemotherapy (NAC) have been described. These results are associated with triple-negative (TNBC) and human epidermal growth factor receptor 2 (HER2+) subtypes achieving pathologic complete response (pCR). This study evaluates predictive variables and survival in order to assess the possible omission of SLNB after NAC. MATERIALS AND METHODS: Prospective study of women with cN0 BC treated with NAC and subsequent surgery, between April 2010 and May 2021...
April 2024: European Journal of Breast Health
#39
JOURNAL ARTICLE
Tuba Kayan Tapan, Filiz Çelebi, Kourosh Yaghouti, Filiz Ağaçayak, Serkan İlgün, Gürsel Soybir, Gül Alço, Naziye Ak, Çetin Ordu, Enver Özkurt, Çağlar Ünal, Sevgi Kurt, Alper Öztürk, Zeynep İyigün, Tomris Duymaz, Vahit Özmen
OBJECTIVE: Differences in individual muscle/fat volumes may change the effectiveness of chemotherapy. In this study, the relationship between trunkal muscle and fat volume and body mass index (BMI) obtained before receiving neoadjuvant chemotherapy (NCT) in patients with breast cancer and complete pathological response (pCR) was investigated. MATERIALS AND METHODS: The volumes of psoas, abdominal and paraspinal muscles, and trunkal subcutaneous and visceral fat were calculated using CoreSlicer AI 2...
April 2024: European Journal of Breast Health
#40
JOURNAL ARTICLE
Yutaka Yamamoto, Chikako Yamauchi, Tatsuya Toyama, Shigenori Nagai, Takehiko Sakai, Goro Kutomi, Michio Yoshimura, Masaaki Kawai, Shoichiro Ohtani, Kazunori Kubota, Kazutaka Nakashima, Naoko Honma, Masayuki Yoshida, Eriko Tokunaga, Naruto Taira, Hiroji Iwata, Shigehira Saji
The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition was published in June 2022. The guidelines were prepared while conforming as much as possible to the "Minds Manual for Guideline Development 2020 ver. 3.0." edited by the Minds Manual Development Committee of the Japan Council for Quality Health Care in 2021. In addition, a survey of Japanese Breast Cancer Society members on the 2018 edition of the guidelines was conducted from February 19 to March 4, 2021. Based on the responses from over 600 members, original innovations were made to make the guidelines more user-friendly...
April 3, 2024: Breast Cancer: the Journal of the Japanese Breast Cancer Society
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
